Trials / Conditions / Supratentorial Glioblastoma

Supratentorial Glioblastoma

9 registered clinical trials studyying Supratentorial Glioblastoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) NCT05052957	Leland Metheny	Phase 2
Completed	LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma NCT04479241	Istari Oncology, Inc.	Phase 2
Withdrawn	Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolom NCT04105374	NRG Oncology	Phase 2 / Phase 3
Unknown	Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas. NCT03997136	Assiut University	—
Completed	18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Gliobl NCT03732352	Jonsson Comprehensive Cancer Center	Phase 2
Active Not Recruiting	Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma NCT03197506	Mayo Clinic	Phase 2
Completed	Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Gliobla NCT02311920	National Cancer Institute (NCI)	Phase 1
Terminated	Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Gliob NCT01430351	M.D. Anderson Cancer Center	Phase 1
Completed	Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Gliob NCT00884741	National Cancer Institute (NCI)	Phase 3